



Australian Government

Department of Health and Aged Care

Third Report on Key Performance Measures (KPM)
for the
Seventh Community Pharmacy Agreement (7CPA)

May 2023

Contents

Index of Tables.....	2
Introduction.....	3
Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians	4
a) Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).....	4
b) Transparency of charges (7CPA, Clause 4.3).	14
c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).	15
d) Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).	16
Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies	17
The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).	17
Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.	18
a) Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).	18
b) Accreditation of pharmacists for undertaking medication reviews.....	19
Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines	21
Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas	23

Index of Tables

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies).....	5
Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies).....	5
Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)	6
Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)	6
Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies).....	6
Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies).....	7
Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2021.....	8
Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022	9
Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022.....	10
Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)	11
Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies).....	11
Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions	12
Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory.....	13
Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories*	15
Table 1(d): Total expenditure on Electronic Prescription Fees	16
Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid.....	17
Table 3(b)-1: Number and percentage of accredited registered pharmacists eligible to provide HMR and RMMR	19
Table 3(b)-2: Number and percentage of accredited pharmacists actively providing HMRs and RMMRs	20
Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services	21
Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance.....	22
Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services	24

Introduction

Key Performance Measures (KPM) for the Seventh Community Pharmacy Agreement (7CPA) were developed as an evaluation framework for operation of the 7CPA. The KPM aim to enable Government, the pharmacy sector and the community to assess impacts of the 7CPA, based on the available evidence, and whether objectives and health outcomes have been achieved effectively and efficiently under the 7CPA.

The KPM are a new undertaking under the 7CPA. No other evaluation mechanisms were developed under previous Community Pharmacy Agreements. As no specific funding has been made available under the 7CPA for monitoring and evaluation, the KPM have been confined to measures that stem from existing processes, available data and resources, with no additional costs to Government.

The KPM were developed in collaboration between the Department and key stakeholders including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Consumers Health Forum of Australia and the National Aboriginal Community Controlled Health Organisation.

KPM reports will be published on a biannual basis, subject to the availability of required data. The KPM will be reviewed in consultation with key stakeholders, named above.

Key objectives and outcomes to be monitored for the 7CPA are to:

1. Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians
2. Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies
3. Support professional initiatives for pharmacists to better fulfil their current scope of practice
4. Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines; and
5. Support access to medicines and pharmacy services for Australians in regional, rural, and remote areas.

This is the third KPM report, presenting information relevant to the following three six-month reporting periods under the 7CPA:

1 July – 31 December 2021, 1 January – 30 June 2022, 1 July – 31 December 2022

The information in this document should be read in conjunction with the [7CPA – Key Performance Measures and monitoring arrangements](#) and [Key Policy Principles – KPM for 7CPA](#), which are each available on the Department of Health and Aged Care's [website](#). The first and second KPM reports can also be accessed at: <https://www.health.gov.au/resources/collections/7cpa-key-performance-measures>.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

a) **Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).**

The following tables present information on:

- Total prescriptions and expenditure for s90 pharmacies¹, for PBS and Repatriation Pharmaceutical Benefits Scheme (RPBS) items by patient category and state / territory – *Tables 1(a)-1, 1(a)-2, 1(a)-3, 1(a)-4, 1(a)-5, 1(a)-7, 1(a)-8 and 1(a)-9*
- Patient contribution and Government cost for PBS items dispensed by s90 pharmacies – *Table 1(a)-6*
- Over and under co-payment PBS prescriptions for items dispensed by s90 pharmacies – *Table 1(a)-2*
- Discounted and non-discounted PBS/RPBS items dispensed by s90 pharmacies – *Tables 1(a)-10 and 1(a)-11*
- PBS remuneration for s90 pharmacies and wholesalers – *Tables 1(a)-12*
- PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services – *Tables 1(a)-13*

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia. Data were extracted on 20 March 2023. Please note that:

- PBS data does not capture over-the-counter medicines, private prescriptions (non-PBS prescriptions) or public inpatient prescriptions.
- The figures provided are subject to change due to late claims and adjustments by pharmacies.

¹ “**s90 Pharmacies**” are those pharmacies operated by a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises. Other suppliers include approved doctors (usually practising in isolated areas) and approved hospitals.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies)

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	PBS Expenditure	Percentage	PBS Expenditure	Percentage	PBS Expenditure	Percentage
Section 85 - Concessional	\$3,587,795,173	62.3%	\$3,166,222,454	59.2%	\$4,215,967,472	61.7%
Section 85 - General	\$1,319,579,587	22.9%	\$1,349,898,412	25.2%	\$1,694,704,288	24.8%
Doctor's Bag	\$6,792,987	0.1%	\$7,434,412	0.1%	\$27,535,152	0.4%
Section 100	\$843,605,549	14.7%	\$823,316,538	15.4%	\$897,956,183	13.1%
Total	\$5,757,773,296	100.0%	\$5,346,871,816	100.0%	\$6,836,163,095	100.0%

Note: Excludes expenditure for RPBS items.

Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	PBS prescriptions	Percentage	PBS prescriptions	Percentage	PBS prescriptions	Percentage
Concessional Non-Safety Net	56,277,529	50.5%	85,468,956	85.4%	45,073,721	39.3%
Concessional Safety Net	44,391,270	39.9%	5,811,228	5.8%	57,883,761	50.5%
Total Concessional	100,668,799	90.4%	91,280,184	91.2%	102,957,482	89.8%
General Non-Safety Net	7,785,899	7.0%	8,496,950	8.5%	8,456,664	7.4%
General Safety Net	2,730,991	2.5%	109,871	0.1%	3,124,599	2.7%
Total General	10,516,890	9.4%	8,606,821	8.6%	11,581,263	10.1%
Doctors Bag	165,860	0.1%	189,580	0.2%	175,503	0.2%
Total (Over Co-payment)	111,351,549	100.0%	100,076,585	100.0%	114,714,248	100.0%
Under Co-payment scripts	48,466,911		50,797,169		52,647,856	
Total (Over and Under Co-payment)	159,818,460		150,873,754		167,362,104	

Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Concessional Non-Safety Net	\$2,322,869,670	40.3%	\$3,349,075,731	62.6%	\$2,233,738,862	32.7%
Concessional Safety Net	\$1,693,323,829	29.4%	\$230,839,429	4.3%	\$2,438,367,984	35.7%
Total Concessional	\$4,016,193,499	69.8%	\$3,579,915,160	67.0%	\$4,672,106,846	68.3%
General Non-Safety Net	\$1,599,951,483	27.8%	\$1,753,836,385	32.8%	\$1,965,442,682	28.8%
General Safety Net	\$134,835,327	2.3%	\$5,685,860	0.1%	\$171,078,416	2.5%
Total General	\$1,734,786,810	30.1%	\$1,759,522,245	32.9%	\$2,136,521,098	31.3%
Doctors Bag	\$6,792,987	0.1%	\$7,434,412	0.1%	\$27,535,152	0.4%
Total (Over Co-payment)	\$5,757,773,296	100.0%	\$5,346,871,816	100.0%	\$6,836,163,095	100.0%

Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage
Repatriation Non-Safety Net	1,690,524	45.3%	3,073,958	90.9%	1,231,889	34.0%
Repatriation Safety Net	2,045,201	54.7%	309,208	9.1%	2,395,176	66.0%
Total Repatriation	3,735,725	100.0%	3,383,166	100.0%	3,627,065	100.0%

Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies)

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Repatriation Non-Safety Net	\$74,270,792.35	49.9%	\$122,278,592	91.0%	\$71,275,175	42.2%
Repatriation Safety Net	\$74,575,519.13	50.1%	\$12,153,585	9.0%	\$97,664,503	57.8%
Total Repatriation	\$148,846,311	100.0%	\$134,432,177	100.0%	\$168,939,678	100.0%

Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies)

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost
Concessional Non-Safety Net	\$356,789,189	\$2,322,869,670	\$559,827,415	\$3,349,075,731	\$293,847,652	\$2,233,738,862
Concessional Safety Net	\$0	\$1,693,323,829	\$0	\$230,839,429	\$0	\$2,438,367,984
Total Concessional	\$356,789,189	\$4,016,193,499	\$559,827,415	\$3,579,915,160	\$293,847,652	\$4,672,106,846
General Non-Safety Net	\$285,688,978	\$1,599,951,483	\$319,261,425	\$1,753,836,385	\$321,066,551	\$1,965,442,682
General Safety Net	\$17,387,053	\$134,835,327	\$715,408	\$5,685,860	\$20,529,445	\$171,078,416
Total General	\$303,076,031	\$1,734,786,810	\$319,976,832	\$1,759,522,245	\$341,595,996	\$2,136,521,098
Total (excl. Drs Bag)	\$659,865,220	\$5,750,980,309	\$879,804,247	\$5,339,437,405	\$635,443,648	\$6,808,627,944
Doctors Bag	\$0	\$6,792,987	\$0	\$7,434,412	\$0	\$27,535,152
Total (Incl. Drs Bag)	\$659,865,220	\$5,757,773,296	\$879,804,247	\$5,346,871,816	\$635,443,648	\$6,836,163,095

* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.

Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2021

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	17,882,347	13,937,920	11,899,062	4,733,609	5,396,426	1,586,256	255,478	586,431	56,277,529
Concessional Safety Net	14,856,405	10,803,902	9,215,769	3,715,194	3,933,118	1,318,292	90,600	457,990	44,391,270
General Non-Safety Net	2,563,096	1,818,272	1,624,961	483,139	874,586	174,515	77,788	169,542	7,785,899
General Safety Net	941,342	653,429	497,934	180,340	313,799	55,977	9,138	79,032	2,730,991
Total	36,243,190	27,213,523	23,237,726	9,112,282	10,517,929	3,135,040	433,004	1,292,995	111,185,689
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$855,022,099	\$526,396,466	\$451,822,545	\$174,416,933	\$226,425,153	\$56,978,707	\$8,407,094	\$23,400,673	\$2,322,869,670
Concessional Safety Net	\$569,367,413	\$410,131,799	\$344,883,177	\$139,939,639	\$156,374,259	\$50,826,545	\$3,082,309	\$18,718,689	\$1,693,323,829
General Non-Safety Net	\$582,245,386	\$391,875,949	\$278,618,785	\$96,756,044	\$180,829,114	\$30,543,635	\$8,189,718	\$30,892,851	\$1,599,951,483
General Safety Net	\$45,974,717	\$33,540,996	\$23,693,454	\$8,496,971	\$15,926,077	\$2,828,861	\$352,993	\$4,021,258	\$134,835,327
Total	\$2,052,609,615	\$1,361,945,211	\$1,099,017,961	\$419,609,587	\$579,554,602	\$141,177,748	\$20,032,114	\$77,033,471	\$5,750,980,309
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$967,462,788	\$617,249,215	\$525,993,029	\$204,707,059	\$260,394,574	\$66,974,539	\$9,700,535	\$27,177,120	\$2,679,658,859
Concessional Safety Net	\$569,367,413	\$410,131,799	\$344,883,177	\$139,939,639	\$156,374,259	\$50,826,545	\$3,082,309	\$18,718,689	\$1,693,323,829
General Non-Safety Net	\$673,721,430	\$464,141,490	\$335,233,912	\$115,005,093	\$213,151,913	\$36,650,525	\$10,271,684	\$37,464,412	\$1,885,640,461
General Safety Net	\$51,934,847	\$37,804,847	\$26,803,770	\$9,652,803	\$17,920,947	\$3,173,216	\$398,579	\$4,533,372	\$152,222,380
Total	\$2,262,486,478	\$1,529,327,351	\$1,232,913,888	\$469,304,594	\$647,841,693	\$157,624,824	\$23,453,108	\$87,893,594	\$6,410,845,529

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (Section 85 and Section 100 prescriptions).

Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	27,646,960	21,153,765	17,831,256	7,204,947	7,929,709	2,497,069	307,620	897,630	85,468,956
Concessional Safety Net	2,027,964	1,383,481	1,214,205	464,795	473,066	175,704	8,494	63,519	5,811,228
General Non-Safety Net	2,815,800	1,972,755	1,770,277	527,445	952,411	190,529	79,876	187,857	8,496,950
General Safety Net	37,305	29,936	17,936	6,163	12,267	2,087	290	3,887	109,871
Total	32,528,029	24,539,937	20,833,674	8,203,350	9,367,453	2,865,389	396,280	1,152,893	99,887,005
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$1,194,373,832	\$775,214,401	\$655,211,556	\$262,201,009	\$327,563,083	\$88,509,999	\$10,013,491	\$35,988,360	\$3,349,075,731
Concessional Safety Net	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
General Non-Safety Net	\$633,055,471	\$427,862,141	\$306,999,143	\$107,975,641	\$199,393,377	\$34,439,187	\$8,593,886	\$35,517,539	\$1,753,836,385
General Safety Net	\$1,885,601	\$1,663,153	\$879,478	\$276,014	\$676,624	\$123,137	\$8,974	\$172,877	\$5,685,860
Total	\$1,908,932,349	\$1,260,235,086	\$1,009,988,437	\$388,848,919	\$547,744,603	\$130,402,667	\$18,904,754	\$74,380,592	\$5,339,437,405
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$1,374,013,730	\$917,339,909	\$770,264,510	\$309,818,159	\$379,276,348	\$104,654,845	\$11,589,534	\$41,946,112	\$3,908,903,146
Concessional Safety Net	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
General Non-Safety Net	\$735,855,407	\$508,393,270	\$370,035,337	\$128,410,173	\$235,473,742	\$41,209,843	\$10,744,544	\$42,975,493	\$2,073,097,810
General Safety Net	\$2,126,689	\$1,863,216	\$993,705	\$316,128	\$755,953	\$136,023	\$10,715	\$198,839	\$6,401,267
Total	\$2,191,613,270	\$1,483,091,785	\$1,188,191,810	\$456,940,714	\$635,617,562	\$153,331,054	\$22,633,195	\$87,822,261	\$6,219,241,652

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2022

Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions

PBS Prescriptions									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	14,315,616	11,165,738	9,614,120	3,742,884	4,300,192	1,240,785	219,860	474,526	45,073,721
Concessional Safety Net	19,119,090	14,237,338	11,939,679	4,883,255	5,258,595	1,723,887	128,049	593,868	57,883,761
General Non-Safety Net	2,786,740	1,994,280	1,754,879	520,491	944,614	187,651	81,633	186,376	8,456,664
General Safety Net	1,057,261	761,460	568,022	206,699	362,108	67,013	10,049	91,987	3,124,599
Total	37,278,707	28,158,816	23,876,700	9,353,329	10,865,509	3,219,336	439,591	1,346,757	114,538,745
Government Cost									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$831,704,665	\$501,275,722	\$429,938,453	\$167,315,936	\$219,417,010	\$52,966,741	\$8,182,341	\$22,937,993	\$2,233,738,862
Concessional Safety Net	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
General Non-Safety Net	\$715,714,696	\$487,108,477	\$339,475,811	\$120,715,366	\$215,484,030	\$37,874,265	\$10,180,168	\$38,889,869	\$1,965,442,682
General Safety Net	\$57,885,521	\$44,257,560	\$28,533,692	\$11,026,931	\$20,066,544	\$3,679,222	\$542,064	\$5,086,881	\$171,078,416
Total	\$2,413,937,318	\$1,635,502,555	\$1,279,752,064	\$505,376,576	\$688,590,287	\$167,905,238	\$23,535,299	\$94,028,607	\$6,808,627,944
Total Cost*									
Categories	NSW	Vic	Qld	SA	WA	Tas	NT	ACT	Australia
Concessional Non-Safety Net	\$924,218,298	\$576,221,671	\$491,562,114	\$191,951,432	\$247,220,939	\$61,015,513	\$9,315,622	\$26,080,926	\$2,527,586,514
Concessional Safety Net	\$808,632,435	\$602,860,796	\$481,804,109	\$206,318,343	\$233,622,702	\$73,385,010	\$4,630,726	\$27,113,863	\$2,438,367,984
General Non-Safety Net	\$818,542,698	\$568,915,178	\$402,790,214	\$141,136,050	\$251,704,159	\$44,658,516	\$12,407,171	\$46,355,246	\$2,286,509,233
General Safety Net	\$64,786,270	\$49,378,892	\$32,184,496	\$12,396,594	\$22,457,887	\$4,104,916	\$597,062	\$5,701,744	\$191,607,860
Total	\$2,616,179,701	\$1,797,376,536	\$1,408,340,933	\$551,802,418	\$755,005,686	\$183,163,955	\$26,950,582	\$105,251,779	\$7,444,071,591

* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Prescription Type	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 July – 31 December 2021	Discounted	21,348,221	21%	3,102,456	29%	470,131	13%	24,920,808	22%
	Non-discounted	79,320,578	79%	7,414,434	71%	3,265,594	87%	90,000,606	78%
	Grand Total	100,668,799	100%	10,516,890	100%	3,735,725	100%	114,921,414	100%
1 January – 30 June 2022	Discounted	25,437,223	28%	2,704,488	31%	597,861	18%	28,739,572	28%
	Non-discounted	65,842,961	72%	5,902,333	69%	2,785,305	82%	74,530,599	72%
	Grand Total	91,280,184	100%	8,606,821	100%	3,383,166	100%	103,270,171	100%
1 July – 31 December 2022	Discounted	17,211,191	16.7%	3,349,610	28.9%	369,922	10.2%	20,930,723	17.7%
	Non-discounted	85,746,291	83.3%	8,231,653	71.1%	3,257,143	89.8%	97,235,087	82.3%
	Grand Total	102,957,482	100.0%	11,581,263	100.0%	3,627,065	100.0%	118,165,810	100.0%

Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies)

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Discount Range	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 July – 31 December 2021	\$1.00	20,875,358	97.8%	3,051,355	98.4%	457,560	97.3%	24,384,273	97.8%
	0.50 - < \$1.00	302,196	1.4%	27,030	0.9%	7,557	1.6%	336,783	1.4%
	< 50c	104,055	0.5%	10,839	0.3%	3,001	0.6%	117,895	0.5%
	Other	66,612	0.3%	13,232	0.4%	2,013	0.4%	81,857	0.3%
	Grand Total	21,348,221	100.0%	3,102,456	100.0%	470,131	100.0%	24,920,808	100.0%
1 January – 30 June 2022	\$1.00	24,811,755	97.5%	2,666,561	98.6%	580,641	97.1%	28,058,957	97.6%
	0.50 - < \$1.00	378,805	1.5%	23,565	0.9%	9,574	1.6%	411,944	1.4%
	< 50c	108,113	0.4%	4,394	0.2%	3,635	0.6%	116,142	0.4%
	Other	138,550	0.5%	9,968	0.4%	4,011	0.7%	152,529	0.5%
	Grand Total	25,437,223	100.0%	2,704,488	100.0%	597,861	100.0%	28,739,572	100.0%
1 July – 31 December 2022	\$1.00	16,822,212	97.7%	3,293,732	98.3%	360,617	97.5%	20,476,561	97.8%
	0.50 - < \$1.00	249,293	1.4%	31,793	0.9%	5,700	1.5%	286,786	1.4%
	< 50c	59,870	0.3%	7,178	0.2%	1,586	0.4%	68,634	0.3%
	Other	79,816	0.5%	16,907	0.5%	2,019	0.5%	98,742	0.5%
	Grand Total	17,211,191	100.0%	3,349,610	100.0%	369,922	100.0%	20,930,723	100.0%

Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to pharmacist for the purchase of medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

Expenses for PBS and RPBS Prescriptions	1 July – 31 December 2021	1 January – 30 June 2022	1 July – 31 December 2022
Medicines Price			
Ex-Manufacturer Price	\$4,236,365,629	\$4,205,920,812	\$5,145,138,722
Wholesale Mark-Up	\$231,742,582	\$225,682,221	\$274,719,201
Total Price to Pharmacist	\$4,468,108,211	\$4,431,603,033	\$5,419,857,923
Pharmacy Costs			
Administration, Handling and Infrastructure (AHI) fee	\$603,588,682	\$555,546,889	\$654,773,696
Dispensing Fee	\$889,213,495	\$797,892,501	\$916,693,173
Dangerous Drug Fee	\$21,398,915	\$19,834,830	\$21,644,848
Wastage Fee	\$3,259,737	\$3,080,697	\$3,438,981
Container Fee	\$619,663	\$516,403	\$426,710
Total Pharmacy Remuneration	\$1,518,080,492	\$1,376,871,320	\$1,596,977,408
Total Cost	\$5,986,188,703	\$5,808,474,352	\$7,016,835,331

Data is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory

Report Period	RAHHS Supply	NSW/TAS*	NT	QLD	SA	WA	Australia
1 July – 31 December 2021	Total Items**	4,494	400,269	123,959	32,566	225,864	787,152
	Total Items Cost	\$103,503	\$10,369,125	\$3,501,937	\$848,248	\$5,776,082	\$20,598,895
	Individual Items***	549	265,514	63,811	17,351	140,509	487,734
	Individual Items cost	\$2,699	\$1,313,623	\$315,657	\$85,872	\$695,988	\$2,413,839
1 January – 30 June 2022	Total Items**	5,374	497,489	176,556	32,414	238,777	950,610
	Total Items Cost	\$132,617	\$12,942,427	\$5,197,948	\$888,138	\$5,872,765	\$25,033,896
	Individual Items***	1,645	338,080	108,388	14,298	141,558	603,969
	Individual Items cost	\$8,157	\$1,676,877	\$537,595	\$70,918	\$702,110	\$2,995,656
1 July – 31 December 2022	Total Items**	5,589	526,067	178,418	37,339	256,213	1,003,626
	Total Items Cost	\$142,727	\$13,970,658	\$5,331,177	\$1,015,595	\$6,679,525	\$27,139,682
	Individual Items***	1,526	353,627	113,685	16,278	177,843	662,959
	Individual Items cost	\$7,669	\$1,777,022	\$571,531	\$81,733	\$893,784	\$3,331,739

Note: there are no RAAHS data for VIC and ACT.

* Data for NSW and Tasmania have been aggregated to prevent identification due to low number of individual data points available.

** Total Items includes items supplied in bulk and individually.

*** Items supplied individually are taken from the no. of instances of the Patient Specific Medicine Supply Fee (PSMSF) paid for each PBS medicine ordered on a RAAHS prescription, and labelled for an individual patient, for supply through an approved RAAHS.

The PSMSF is paid in addition to the handling fee paid to eligible pharmacies for the supply of bulk PBS medicines to an approved RAAHS.

The PSMSF figures are a subset of the RAAHS figures.

From 1 July 2021 to 30 June 2022 the PSMSF was \$4.96 and from 1 July 2022 to 30 June 2023 is \$5.04.

The PSMSF data has been manually extracted from Services Australia Remote Area Aboriginal Health Services Access data base and is not sourced from official channels.

This data relates to the date claims are processed and may differ from other data provided by Services Australia, including PBS Expenditure data.

PSMSF values maybe affected by rounding

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

b) **Transparency of charges (7CPA, Clause 4.3).**

Clause 4.3 of the Seventh Community Pharmacy Agreement (7CPA) committed the Pharmacy Guild of Australia (Guild) to ensuring that Approved Pharmacists² “make consumers aware, prior to dispensing a Pharmaceutical Benefit, of any Safety Net Recording Fee and Additional Patient Charge to be charged, the fact that the Additional Patient Charge is not Commonwealth initiated, and the total cost to the consumer of that Pharmaceutical Benefit.” During the First Financial Year of the 7CPA, the Guild was required to work with the Department to develop arrangements and processes to support this commitment.

Following discussion at the first meeting of the 7CPA Pharmacy Stakeholder Consultation Committee (PSCC) in October 2020, the Guild worked with the Department to develop arrangements and processes for Approved Pharmacists to make the required disclosures and to notify consumers, prior to dispensing, of the price of the Pharmaceutical Benefit.

The draft communication resources and materials developed by the Guild, consisting of an in-pharmacy poster and supporting Frequently Asked Questions (FAQ), were subsequently discussed at the second PSCC meeting in April 2021, with further consultations between the Department, the Pharmaceutical Society of Australia (PSA), Consumers Health Forum of Australia (CHF) and the National Aboriginal Community Controlled Health Organisation (NACCHO), leading to consumer focus testing hosted by CHF and the Guild.

Following endorsement of the Guild’s communication resources by PSCC in July 2021, the resources were published on the Guild’s [FindaPharmacy](#) website on 1 January 2022, to coincide with annual PBS patient co-payment changes.

The Guild will continue to provide regular updates on progress and uptake of its PBS medicines pricing resources at biannual meetings of the PSCC. Communiqués arising from each meeting of the PSCC are published on the [Department’s website](#).

² An “**approved pharmacist**” means a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from a particular pharmacy premises.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).

The CTG PBS Co-payment program was established in July 2010 to improve access to affordable PBS medicines for Aboriginal and Torres Strait Islander people living with, or at risk of, chronic disease, and who in their doctor's opinion would experience setbacks in the prevention or ongoing management of chronic disease if they did not take the prescribed medicine and would be unlikely to adhere to their medicines regimen without assistance through the program.

When obtaining PBS General Schedule medicines at their local pharmacy, eligible general patients who would normally pay the full PBS co-payment pay the concessional rate and those eligible patients who would normally pay the concessional rate receive their PBS medicines without being required to pay a PBS co-payment.

The following table presents information on the total number of PBS items and expenditure for the CTG PBS Co-Payment Program across states and territories. This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories*

Pharmacy State/Territory	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount
ACT	36,572	\$306,032	38,044	\$388,038	37,853	\$304,457
NSW	1,678,691	\$10,933,459	1,670,425	\$14,591,200	1,685,396	\$10,690,194
NT	117,227	\$912,899	112,822	\$1,066,306	117,191	\$920,885
QLD	1,349,344	\$9,096,850	1,310,573	\$11,514,246	1,330,385	\$8,762,770
SA	269,215	\$1,692,801	266,958	\$2,226,997	265,021	\$1,565,180
TAS	174,459	\$1,011,864	174,733	\$1,454,866	174,731	\$969,395
VIC	331,688	\$2,154,362	333,794	\$2,903,246	332,423	\$2,068,862
WA	460,586	\$3,196,985	442,403	\$3,927,907	442,448	\$3,015,821
Total	4,417,782	\$29,305,252	4,349,752	\$38,072,805	4,385,448	\$28,297,565

* The data provided is inclusive of PBS and RPBS items and expenditure.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

d) **Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).**

Electronic prescribing provides an option for prescribers and their patients to use an electronic prescription as an alternative to a paper prescription. Electronic prescriptions are part of the broader digital health and medicines safety framework and are part of an Australian Government budget measure to make the PBS more efficient. Electronic prescribing aims to provide convenience and choice to patients while improving PBS efficiency, compliance and medicines safety. Electronic prescribing does not fundamentally change existing prescribing and dispensing processes: patients can still choose which pharmacy they attend to fill their prescription; and paper prescriptions are still available.

An Electronic Prescription Fee (EPF) is paid to pharmacies for the dispensing of electronic prescriptions.

Under the 7CPA (clause 9.4), the Commonwealth continues to support the uptake of electronic prescriptions by Approved Pharmacists. Following the first financial year of the 7CPA, the EPF will transition to a direct funding arrangement with Exchange Infrastructure Providers rather than Approved Pharmacists.

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

Table 1(d): Total expenditure on Electronic Prescription Fees

Cost (PBS and RPBS Prescriptions)	1 July – 31 December 2021	1 January – 30 June 2022	1 July – 31 December 2022
Electronic Prescription Fee	\$9,626,492	\$9,705,446	\$11,724,385

Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).

Approved community pharmacy Access Points receive a payment of \$1 plus GST for each NDSS product pack supplied to registrants.

Community Service Obligation Distributors (CSODs) receive a payment of \$1 plus GST for each NDSS product pack delivered to NDSS Access Points.

Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid

Category	1 July – 31 December 2021	1 January – 30 June 2022	1 July – 31 December 2022
Total No. of NDSS registrants	1,426,245	1,454,169	1,487,300
Registrants registered on the NDSS Gestational Diabetes Mellitus Reminder Register	169,543	175,476	229,291
Total No. of approved community pharmacy NDSS Access Points	5,650	5,904	5,923
Total Access Point Fees Paid	\$3,370,193	\$3,142,066	\$3,636,145

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

a) ***Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).***

Clause 14.2 of the Seventh Community Pharmacy Agreement (7CPA) commits the Pharmaceutical Society of Australia (PSA) and the Department of Health and Aged Care, to working together in relation to the further development of the PSA Code of Ethics that underpins pharmacist practice in Australia.

The Department has chosen not to pursue an update of the PSA Code of Ethics at this time, following a review of PSA's proposal submitted in late 2021.

Clause 14.6 of the 7CPA commits the PSA to continue to maintain the Professional Practice Standards (PPS) and relevant clinical guidelines with the aim of providing pharmacists with practice information to support the safe and quality use of medicines.

As part of this work, the Department entered into a contract with PSA in October 2021, to redevelop the Guidelines for Medication Management for Aboriginal and Torres Strait Islander people. This was successfully completed and the redeveloped [Guidelines for Pharmacists supporting Aboriginal and Torres Strait Islander Peoples with Medicines Management](#) published in July 2022.

In April 2022, the Department entered into a contract with PSA to update the PPS. A draft version of the updated PPS was released for public consultation, which closed in March 2023. The updated PPS is expected to be released by mid-2023.

As part of this work, the PSA will also update some clinical guidelines, including those associated with Continuous Dispensing arrangements.

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

b) Accreditation of pharmacists for undertaking medication reviews

Home Medicines Reviews (HMR) and Residential Medication Management Reviews (RMMR) are medication management services initiated and supported by the Australian Government, aimed at supporting the quality use of medicines and assisting in minimising adverse medicine events by helping people understand and manage their medicines. Medication reviews are initiated by a medical practitioner and conducted by an accredited pharmacist. The HMR involves an accredited pharmacist making a home visit to a patient's home to provide a medication review service, while the RMMR service is provided to an eligible patient residing in an eligible Residential Care Facility. In both HMR and RMMR, after the initial interview, the accredited pharmacist provides an HMR or RMMR report respectively to the initiating medical practitioner for consideration of issues raised.

From 21 April 2020, if clinically indicated, up to two follow-up services may be conducted to resolve medication-related problems identified at the initial interview.

Table 3(b)-1: Number and percentage of accredited registered pharmacists eligible to provide HMR and RMMR

Category	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Number	Percentage	Number	Percentage	Number	Percentage
Accredited registered pharmacists	1977 ^a	5.4%	2141 ^c	6.1%	2,836 ^e	7.9%
Total No. of registered pharmacists	36,283 ^b		35,368 ^d		35,732 ^f	

a - as at 13 May 2022. Information sourced from data published by [The Society of Hospital Pharmacy of Australia \(SHPA\)](#), [Australian Association of Consultant Pharmacy \(AACCP\)](#) and [Pharmacy Board of Australia \(PBA\)](#).

b - as at 31 March 2022. Includes 1,888 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

c - as at 31 October 2022. Information sourced from data published by [The Society of Hospital Pharmacy of Australia \(SHPA\)](#), [Australian Association of Consultant Pharmacy \(AACCP\)](#) and [Pharmacy Board of Australia \(PBA\)](#).

d - as at 30 June 2022. Includes 642 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

e - as at 19 December 2022. Information sourced from data published by [The Society of Hospital Pharmacy of Australia \(SHPA\)](#), [The Accredited Pharmacist Issue 22/22](#) dated 19 December 2022 and [Pharmacy Board of Australia \(PBA\)](#).

f - as of 31 December 2022. Includes 125 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

Note: An accredited pharmacist can provide both HMR and RMMR services.

Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice

Table 3(b)-2: Number and percentage of accredited pharmacists actively providing HMRs and RMMRs

	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
Category	Number	Percentage	Number	Percentage	Number	Percentage
Average No. of accredited pharmacists actively providing HMR/RMMR services ^a	1,168	59.1%	1,074	50.2%	1,250	44.1%
Total No. of accredited pharmacists	1,977		2,141		2,836	

a - Information sourced from data published by [7CPA Pharmacy Programs Data](#) (last updated 17 March 2023) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

The 7CPA provides funding for professional pharmacy programs and services over the life of the Agreement. These programs include continuation and revision of existing pharmacy programs and services from the 6CPA and include:

- **Medication Adherence Programs:** Dose Administration Aids (DAA) and Staged Supply
- **Medication Management Programs:** MedsCheck, Diabetes MedsCheck, Home Medicines Review (HMR), Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) in Residential Aged Care Facilities
- **Aboriginal and Torres Strait Islander Programs:** Indigenous Dose Administration Aids (IDAA) Program and Indigenous Health Services Pharmacy Support (IHSPS) Program

Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services

Program or Service	1 July – 31 December 2021		1 Jan- 30 June 2022		1 July – 31 December 2022	
	Total Services	Expenditure	Total Services	Expenditure	Total Services	Expenditure
Dose Administration Aids	7,932,725	\$49,136,220.04	7,913,876	\$49,031,496.86	7,977,630	\$49,368,323
Indigenous Dose Administration Aids	635,108	\$7,516,556.40	842,841	\$9,950,897.60	903,094	\$10,577,216
Staged Supply	95,958	\$4,598,978.72	92,816	\$4,452,731.48	97,258	\$4,535,245
HMR*	60,483	\$11,597,387.77	73,026	\$11,167,055.07	79,891	\$14,732,760.43
RMMR*	77,574	\$7,798,830.17	85,942	\$6,759,047.87	80,010	\$7,857,906.29
MedsCheck	203,819	\$13,560,078.07	185,371	\$12,332,732.63	206,511	\$13,739,178.67
Diabetes MedsCheck	73,837	\$7,368,194.23	74,693	\$7,453,614.47	90,427	\$9,023,714.47
Quality Use of Medicines in Residential Aged Care Facilities	2,864 ^a	\$5,942,352.86	2,664 ^a	\$5,562,931.48	2,625 ^a	\$5,694,451.06

* Total services for HMR and RMMR programs are inclusive of services paid for first and second follow up.

^a – this item reports the average number of participating service providers for this service in any one month during the reporting period. Please note that it does not represent the number of services provided.

Information sourced from [7CPA- Pharmacy programs data](#) (last updated 17 March 2023) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

Indigenous Health Services Pharmacy Support (IHSPS) Program

The IHSPS Program was created by merging the Quality Use of Medicines Maximised for Aboriginal & Torres Strait Islander People (QUMAX) and S100 Pharmacy Support Allowance programs, which continued from the 6CPA during the first year of the 7CPA (until 30 June 2021).

The IHSPS Program commenced in July 2021. Table 4-2 below shows the reduction in expenditure during the changeover from QUMAX and S100 Pharmacy Support Allowance programs to the IHSPS program.

Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance

Program	1 July – 31 December 2021		1 January – 30 June 2022		1 July – 31 December 2022	
	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure
QUMAX*	N/A	\$60,414.74	N/A	N/A	N/A	N/A
S100 Pharmacy Support Allowance*	N/A	\$399,000.00	N/A	N/A	N/A	N/A
IHSPS Program	225	\$1,958,320.75	225	\$1,086,942.26	228	\$2,584,281.64

* Both QUMAX and S100 Pharmacy Support Allowance programs ceased as stand-alone programs on 30 June 2021. Expenditure for these programs recorded after this date represent payments for residual claims.

Information sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) (last updated 31 January 2023) published by the Department of Health and Aged Care.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas

Rural Support Programs are targeted programs and services to support access to PBS medicines and pharmacy services for people living in regional, rural and remote regions of Australia. Services supported under the 7CPA include:

- Regional Pharmacy Maintenance Allowance
- Rural Continuing Professional Education Allowance
- Emergency Locum Service
- Intern Incentive Allowance for Rural Pharmacists
- Incentive Allowance for Rural Pharmacies- Extension Program
- Rural Intern Training Allowance
- Rural Pharmacy Scholarship Scheme
- Rural Pharmacy Scholarship Mentor Scheme
- Rural Pharmacy Liaison Officer Program
- Rural Pharmacy Student Placement Allowance Program and Administrative Support to Pharmacy Schools Scheme

Table 5 (below) provides information on the number of participants and the total expenditure for each of the above programs.

Note that service providers differ based on specific programs and include pharmacists, pharmacy educators, universities and pharmacy interns, in addition to rural and remote hospital and community pharmacies.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services

Program	1 July – 31 December 2021		1 January – 30 June 2022 *		1 July – 31 December 2022	
	Item	Expenditure	Item	Expenditure	Item	Expenditure
Regional Pharmacy Maintenance Allowance (RPMA)	1049 ^a	\$9,831,037.99	1061 ^{a *}	\$9,893,154.40 *	1,079 ^a	\$9,888,853.34
Rural Continuing Professional Education Allowance (CPE)	48 ^b	\$42,715.34	68 ^b	\$67,536.38	76 ^b	\$76,468.12
Emergency Locum Service (ELS)	36 ^{5c}	\$39,070.81	63 ^c	\$69,756.39	36 ^c	\$64,718.55
Intern Incentive Allowance for Rural Pharmacies (IIARP)	36 ^d	\$111,666.67	52 ^{d5}	\$269,166.67	44.5 ^d	\$142,500.01
Intern Incentive Allowance for Rural Pharmacies - Extension Program (IIRP-EP)	5 ^d	\$45,000.00	9.5 ^d	\$70,000.00	8.5 ^d	\$71,666.67
Rural Intern Incentive Allowance (RITA)	34 ^b	\$19,389.61	21 ^b	\$11,572.97	73 ^b	\$36,663.24
Rural Pharmacy Scholarship Scheme (RPSS)	66 ^d	\$324,500.00	64 ^d	\$284,000.00	52 ^d	\$251,000.00
Rural Mentor Scheme (RMS)	73 ^d	\$21,750.00	74 ^d	\$4,125 *	80.5 ^d	\$16,500.00
Rural Pharmacy Liaison Officer (RPLO)	9 ^d	\$403,500.00	9 ^d	\$193,500.00	9 ^d	\$355,500.00
Rural Pharmacy Student Placement Allowance (RPSPA)	16 ^e	\$278,587.99	16 ^e	\$219,131.80	16 ^e	\$273,819.35
Administrative Support to Pharmacy Schools Scheme (ASPSS)	16 ^e	\$205,625.00	16 ^e	\$95,468.75	16 ^e	\$198,281.25
Aboriginal and Torres Strait Islander Pharmacy Scholarship Scheme (ATSIPSS)	8 ^d	\$60,000.00	3.5 ^d	\$30,000.00	4 ^d	\$30,000.00

The items reported are; a-Average number of active service providers for RPMA, b- No. of approved claims, c- No. of locum placements, d- Average no. of active participants, e-Average no. of participating universities. This information was sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) (last updated 31 January 2023) published by the Department of Health and Aged Care.

* Note that certain figures for the period 1 January – 30 June 2022, relating to item/expenditure data for RPMA, IIARP and RMS, were incorrectly reported in the Second Report on KPM for the 7CPA. These figures have been corrected in this report.